vs
Side-by-side financial comparison of Eightco Holdings Inc. (ORBS) and STRATA Skin Sciences, Inc. (SSKN). Click either name above to swap in a different company.
Eightco Holdings Inc. is the larger business by last-quarter revenue ($10.2M vs $9.3M, roughly 1.1× STRATA Skin Sciences, Inc.). STRATA Skin Sciences, Inc. runs the higher net margin — 0.6% vs -2281.6%, a 2282.2% gap on every dollar of revenue. On growth, STRATA Skin Sciences, Inc. posted the faster year-over-year revenue change (-3.0% vs -49.9%). STRATA Skin Sciences, Inc. produced more free cash flow last quarter ($-551.0K vs $-11.0M). Over the past eight quarters, STRATA Skin Sciences, Inc.'s revenue compounded faster (17.3% CAGR vs 13.1%).
Strata Skin Sciences is an American medical device company focused on the design, development and commercialization of non-invasive tools to provide additional information to dermatologists during melanoma skin examinations.
ORBS vs SSKN — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $10.2M | $9.3M |
| Net Profit | $-232.5M | $58.0K |
| Gross Margin | -13.0% | 61.8% |
| Operating Margin | -475.0% | 5.3% |
| Net Margin | -2281.6% | 0.6% |
| Revenue YoY | -49.9% | -3.0% |
| Net Profit YoY | -9183.3% | 101.3% |
| EPS (diluted) | $-2.34 | $0.14 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $10.2M | $9.3M | ||
| Q3 25 | $5.3M | $6.9M | ||
| Q2 25 | $7.6M | $7.7M | ||
| Q1 25 | $9.9M | $6.8M | ||
| Q4 24 | $20.3M | $9.6M | ||
| Q3 24 | $6.1M | $8.8M | ||
| Q2 24 | $5.3M | $8.4M | ||
| Q1 24 | $8.0M | $6.8M |
| Q4 25 | $-232.5M | $58.0K | ||
| Q3 25 | $-25.8M | $-1.6M | ||
| Q2 25 | $-1.2M | $-2.6M | ||
| Q1 25 | $-2.5M | $-2.1M | ||
| Q4 24 | $-2.5M | $-4.6M | ||
| Q3 24 | $-3.2M | $-2.1M | ||
| Q2 24 | $4.4M | $-91.0K | ||
| Q1 24 | $1.9M | $-3.4M |
| Q4 25 | -13.0% | 61.8% | ||
| Q3 25 | -3.7% | 60.4% | ||
| Q2 25 | 16.4% | 56.2% | ||
| Q1 25 | 8.2% | 53.5% | ||
| Q4 24 | 8.2% | 61.4% | ||
| Q3 24 | 26.5% | 60.1% | ||
| Q2 24 | 25.1% | 59.0% | ||
| Q1 24 | 17.5% | 45.6% |
| Q4 25 | -475.0% | 5.3% | ||
| Q3 25 | -116.9% | -16.9% | ||
| Q2 25 | -15.9% | -30.1% | ||
| Q1 25 | -14.3% | -25.0% | ||
| Q4 24 | -11.9% | -44.7% | ||
| Q3 24 | -29.1% | -18.2% | ||
| Q2 24 | -16.4% | -5.7% | ||
| Q1 24 | -39.6% | -42.7% |
| Q4 25 | -2281.6% | 0.6% | ||
| Q3 25 | -487.6% | -23.4% | ||
| Q2 25 | -15.4% | -33.6% | ||
| Q1 25 | -25.7% | -31.2% | ||
| Q4 24 | -12.3% | -47.6% | ||
| Q3 24 | -52.5% | -23.6% | ||
| Q2 24 | 84.2% | -1.1% | ||
| Q1 24 | 24.4% | -49.8% |
| Q4 25 | $-2.34 | $0.14 | ||
| Q3 25 | $-0.58 | $-0.36 | ||
| Q2 25 | $-0.38 | $-0.62 | ||
| Q1 25 | $-0.84 | $-0.51 | ||
| Q4 24 | $-1.44 | $-2.01 | ||
| Q3 24 | $-1.77 | $-0.51 | ||
| Q2 24 | $2.15 | $-0.03 | ||
| Q1 24 | $1.42 | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $58.5M | $7.9M |
| Total DebtLower is stronger | — | $15.3M |
| Stockholders' EquityBook value | $232.6M | $2.9M |
| Total Assets | $250.2M | $30.5M |
| Debt / EquityLower = less leverage | — | 5.28× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $58.5M | $7.9M | ||
| Q3 25 | $23.7M | $7.1M | ||
| Q2 25 | $696.3K | $6.0M | ||
| Q1 25 | $434.4K | $6.5M | ||
| Q4 24 | $239.2K | $7.3M | ||
| Q3 24 | $2.4M | $7.1M | ||
| Q2 24 | $363.1K | $5.5M | ||
| Q1 24 | $808.8K | $5.2M |
| Q4 25 | — | $15.3M | ||
| Q3 25 | — | $15.3M | ||
| Q2 25 | — | $15.0M | ||
| Q1 25 | — | $15.0M | ||
| Q4 24 | — | $15.0M | ||
| Q3 24 | — | $15.0M | ||
| Q2 24 | — | $15.0M | ||
| Q1 24 | — | $15.0M |
| Q4 25 | $232.6M | $2.9M | ||
| Q3 25 | $339.2M | $1.3M | ||
| Q2 25 | $8.9M | $532.0K | ||
| Q1 25 | $9.7M | $3.0M | ||
| Q4 24 | $11.9M | $5.0M | ||
| Q3 24 | $13.0M | $9.4M | ||
| Q2 24 | $13.8M | $9.5M | ||
| Q1 24 | $3.9M | $9.4M |
| Q4 25 | $250.2M | $30.5M | ||
| Q3 25 | $355.5M | $30.7M | ||
| Q2 25 | $48.7M | $29.5M | ||
| Q1 25 | $47.6M | $33.0M | ||
| Q4 24 | $50.8M | $34.9M | ||
| Q3 24 | $49.2M | $39.4M | ||
| Q2 24 | $48.4M | $38.8M | ||
| Q1 24 | $50.2M | $39.2M |
| Q4 25 | — | 5.28× | ||
| Q3 25 | — | 11.65× | ||
| Q2 25 | — | 28.20× | ||
| Q1 25 | — | 5.04× | ||
| Q4 24 | — | 3.02× | ||
| Q3 24 | — | 1.60× | ||
| Q2 24 | — | 1.58× | ||
| Q1 24 | — | 1.59× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-11.0M | $-239.0K |
| Free Cash FlowOCF − Capex | $-11.0M | $-551.0K |
| FCF MarginFCF / Revenue | -107.7% | -5.9% |
| Capex IntensityCapex / Revenue | 0.0% | 3.4% |
| Cash ConversionOCF / Net Profit | — | -4.12× |
| TTM Free Cash FlowTrailing 4 quarters | — | $-4.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-11.0M | $-239.0K | ||
| Q3 25 | $-1.6M | $-64.0K | ||
| Q2 25 | $-659.2K | $-1.9M | ||
| Q1 25 | $999.8K | $-550.0K | ||
| Q4 24 | $-6.6M | $703.0K | ||
| Q3 24 | $77.7K | $-302.0K | ||
| Q2 24 | $-440.3K | $591.0K | ||
| Q1 24 | $-723.3K | $-804.0K |
| Q4 25 | $-11.0M | $-551.0K | ||
| Q3 25 | — | $-1.1M | ||
| Q2 25 | $-661.3K | $-2.0M | ||
| Q1 25 | $999.7K | $-749.0K | ||
| Q4 24 | $-6.6M | $199.0K | ||
| Q3 24 | $73.0K | $-364.0K | ||
| Q2 24 | — | $246.0K | ||
| Q1 24 | — | $-1.5M |
| Q4 25 | -107.7% | -5.9% | ||
| Q3 25 | — | -15.6% | ||
| Q2 25 | -8.7% | -26.1% | ||
| Q1 25 | 10.1% | -11.0% | ||
| Q4 24 | -32.7% | 2.1% | ||
| Q3 24 | 1.2% | -4.1% | ||
| Q2 24 | — | 2.9% | ||
| Q1 24 | — | -22.6% |
| Q4 25 | 0.0% | 3.4% | ||
| Q3 25 | 0.0% | 14.7% | ||
| Q2 25 | 0.0% | 0.8% | ||
| Q1 25 | 0.0% | 2.9% | ||
| Q4 24 | 0.0% | 5.3% | ||
| Q3 24 | 0.1% | 0.7% | ||
| Q2 24 | — | 4.1% | ||
| Q1 24 | — | 10.7% |
| Q4 25 | — | -4.12× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -0.10× | — | ||
| Q1 24 | -0.37× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ORBS
Segment breakdown not available.
SSKN
| Dermatology Recurring Procedures | $6.1M | 65% |
| Dermatology Procedures Equipment | $3.2M | 35% |
